Advertisement

Monitoring of Serum HLA Class I Antigen Levels in Allogeneic Bone Marrow Transplantation

  • Francesco Puppo
  • Sabrina Brenci
  • Massimo Ghio
  • Donatella Bignardi
  • Paola Contini
  • Andrea Bacigalupo
  • Maria T. Van Lint
  • Gilberto Filaci
  • Marco Scudeletti
  • Soldano Ferrone
  • Francesco Indiveri

Abstract

The levels of serum HLA Class I antigens were determined at weekly intervals up to five weeks in thirty-eight patients who had undergone allogeneic BMT. In patients with GVHD grade I serum HLA Class I antigen levels did not change during the observation period. In patients with GVHD grade II – IV serum HLA Class I antigen level increased in the week before the onset of GVHD and was maximal during the GVHD episode. The mean ± SEM concentrations of serum HLA Class I antigens during GVHD grade II – IV episodes (6.3 ±1.1 jig/ml) is significantly higher than in the first week after BMT (2.5 ± 0.3 lng/ml) and in the week preceding the GVHD episode (3.5 ± 0.4 ug/ml) (P = 0.0002 and P = 0.01, respectively). The results of the present investigation suggest that measure of serum HLA Class I antigen level may be a useful marker to detect an acute GVHD following BMT.

Keywords

Graft Versus Host Disease Antigen Level Allogeneic Bone Marrow Transplantation Bone Marrow Transplantation Recipient Acute Graft Versus Host Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Natali PG, Bigotti A, Nicotra MR, Viora M, Manfredi D, Ferrone S: Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res 44: 4679, 1984.PubMedGoogle Scholar
  2. 2.
    Van Rood J J, van Leeuwen A, van Santen MCT: Anti HL-A2 inhibitor in normal human serum. Nature 226: 366, 1970.PubMedCrossRefGoogle Scholar
  3. 3.
    Charlton RK, Zmijewski CM: Soluble HL-A7 antigen: localization in the ß-lipoprotein fraction of human serum. Science 170: 636, 1970.PubMedCrossRefGoogle Scholar
  4. 4.
    Pellegrino MA, Ferrone S, Pellegrino AG, Oh SK, Reisfeld RA: Evaluation of two sources of soluble HL-A antigens: platelets and serum. Eur J Immunol 4: 246, 1974.CrossRefGoogle Scholar
  5. 5.
    Ferrone S, Pellegrino MA, Billing R, Terasaki PI, Reisfeld RA: Production of anti-W24 xenoantisera in rabbits. Tissue Antigens 5: 41, 1975.PubMedCrossRefGoogle Scholar
  6. 6.
    Pellegrino MA, Indiveri F, Fagiolo U, Antonello A, Ferrone S: Immunogenicity of serum HLA antigens in allogeneic combinations. Transplantation 33: 530, 1982.PubMedCrossRefGoogle Scholar
  7. 7.
    Krensky AM, Weiss A, Crabtree G, Davis MM, Parham P: T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 322: 510, 1990.PubMedCrossRefGoogle Scholar
  8. 8.
    Puppo F, Brenci S, Lanza L, Bosco O, Imro MA, Scudeletti M, Indiveri F, Ferrone S: Increased level of serum HLA Class I antigens in HIV infection. Correlation with disease progression. Hum Immunol 40: 259, 1994.PubMedCrossRefGoogle Scholar
  9. 9.
    Saririan K, Wali A, Almeida RP, Russo C: Increased serum HLA class I molecule levels in elderly human responders to influenza vacciantion. Tissue Antigens 42: 9, 1993.PubMedCrossRefGoogle Scholar
  10. 10.
    Davies HffS, Pollard SG, Calne RY: Soluble HLA antigens in the circulation of liver graft recipients. Transplantation 47: 524, 1989.CrossRefGoogle Scholar
  11. 11.
    Pollard SG, Davies HffS, Calne RY: Peroperative appearance of serum class I antigen during liver transplantation. Transplantation 49: 659, 1990.PubMedCrossRefGoogle Scholar
  12. 12.
    Tilg H, Westhoff U, Vogel W, Aulitzky WE, Herold M, Margreiter R, Huber C, Grosse-Wilde H: Soluble HLA class I serum concentrations increase with transplant-related complications after liver transplanta¬tion. J Hepatol 14: 417, 1992.PubMedCrossRefGoogle Scholar
  13. 13.
    Rhynes VK, McDonald JC, Gelder FB, Aultman DF, Hayes JM, McMillan RW, Mancini MC: Soluble HLA Class I in the serum of transplant recipients. Ann Surg 217: 485, 1993.PubMedCrossRefGoogle Scholar
  14. 14.
    Puppo F, Pellicci R, Brenci S, Nocera A, Morelli N, Dardano G, Berlocchi M, Antonucci A, Ghio M, Scudeletti M, Barocci S, Valente U, Indiveri F: HLA Class-I-soluble antigen serum levels in liver transplantation. A predictor marker of acute rejection. Hum Immunol 40: 166, 1994.PubMedCrossRefGoogle Scholar
  15. 15.
    Zavazava N, Böttcher H, Müller-Ruchholz W: Soluble MHC class I antigens (sHLA) and anti-HLA antibodies in heart and kidney allograft recipients. Tissue Antigens 42: 20, 1993.PubMedCrossRefGoogle Scholar
  16. 16.
    DeVito-Haynes LD, Jankowska-Gan E, Sollinger HW, Knechtle SJ, Burlingham WJ: Monitoring of kidney and simultaneous pancreas-kideny transplantation rejection by release of donor-specific, soluble HLA Class I. Hum Immunol 40: 191, 1994.PubMedCrossRefGoogle Scholar
  17. 17.
    Westhoff U, Doxiadis I, Beelen DW, Schaefer UW, Grosse-Wilde H: Soluble HLA Class I concentrations and GVHD after allogeneic marrow transplantation. Transplantation 48: 890, 1989.CrossRefGoogle Scholar
  18. Van Lint MT, Bacigalupo A, Frassoni F, Repetto M, Piaggio G, Congiu M, Vitale V, Scarpati D, Franzone P, Corvo R: Bone marrow transplantation (BMT) for acute lymphoblastic leukemia (ALL) in remission. Haematologica71: 135, 1986.Google Scholar
  19. 19.
    Bacigalupo A, Van Lint MT, Occhini D, Gualandi F, Lamparelli T, Sogno G, Tedone E, Frassoni F, Tong J, Marmont AM: Increased risk of leukemia relapse with high dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 77: 1423, 1991.PubMedGoogle Scholar
  20. 20.
    Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD: Bone-marrow transplantation. N Engl J Med 292: 832, 1975.PubMedCrossRefGoogle Scholar
  21. 21.
    Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler AZ: Production of monoclonal antibodies to group A eryhtrocytes, HLA and other human cell surface antigens: new tools for genetic analysis. Cell 14:9,1978.PubMedCrossRefGoogle Scholar
  22. 22.
    Comuzio s, Puppo F, Ruzzenenti R, Orlandini A, Grillo F, Brenci S, Lanza L, Scudeletti M, Indiveri F: Simple ELISA method for the evaluation of soluble HLA class I antigens in human serum. J Clin Lab Anal 5: 278, 1991.Google Scholar
  23. 23.
    Ferrara JLM, Deeg HJ. Graft-versus-host disease. N Engl J Med 324:667,1991PubMedCrossRefGoogle Scholar
  24. 24.
    Vogelsang g, Hess AD: Graft-versus-host-disease: new directions for a persistent problem. Blood 84:2061, 1994.PubMedGoogle Scholar
  25. 25.
    Russo C, Fotino M, Carbonara A, Ferrone S: A double determinant immunoassay for HLA Class I typing using serum as an antigen source. Hum Immunol 19:69,1987.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New york 1996

Authors and Affiliations

  • Francesco Puppo
    • 1
    • 4
  • Sabrina Brenci
    • 1
  • Massimo Ghio
    • 1
  • Donatella Bignardi
    • 1
  • Paola Contini
    • 1
  • Andrea Bacigalupo
    • 2
  • Maria T. Van Lint
    • 2
  • Gilberto Filaci
    • 1
  • Marco Scudeletti
    • 1
  • Soldano Ferrone
    • 3
  • Francesco Indiveri
    • 1
  1. 1.Department of Internal MedicineUniversity of GenovaItaly
  2. 2.Bone Marrow Transplantation UnitSan Martino HospitalGenovaItaly
  3. 3.Department of Microbiology and ImmunologyNew York Medical CollegeValhallaUSA
  4. 4.DI.M.IGenovaItaly

Personalised recommendations